NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,032,364 | -56.5% | 125,843 | +11.7% | 0.00% | -100.0% |
Q2 2023 | $4,675,722 | -49.1% | 112,668 | -26.2% | 0.00% | -50.0% |
Q1 2023 | $9,178,506 | -54.1% | 152,619 | -44.0% | 0.00% | -50.0% |
Q4 2022 | $19,997,631 | -2.4% | 272,633 | +1.1% | 0.00% | -20.0% |
Q3 2022 | $20,484,000 | +17.4% | 269,597 | +7.4% | 0.01% | +25.0% |
Q2 2022 | $17,442,000 | +3.5% | 250,971 | +23.4% | 0.00% | 0.0% |
Q1 2022 | $16,856,000 | -33.0% | 203,454 | -39.3% | 0.00% | -20.0% |
Q4 2021 | $25,170,000 | -14.3% | 335,234 | +32.6% | 0.01% | -16.7% |
Q3 2021 | $29,366,000 | -49.5% | 252,788 | -3.6% | 0.01% | -53.8% |
Q2 2021 | $58,167,000 | +149.4% | 262,224 | +48.6% | 0.01% | +116.7% |
Q1 2021 | $23,319,000 | -63.6% | 176,422 | -52.4% | 0.01% | -62.5% |
Q4 2020 | $64,086,000 | +165.2% | 370,355 | +70.6% | 0.02% | +166.7% |
Q3 2020 | $24,163,000 | +9.2% | 217,078 | -41.8% | 0.01% | -14.3% |
Q2 2020 | $22,121,000 | -19.8% | 373,034 | -9.0% | 0.01% | -30.0% |
Q1 2020 | $27,593,000 | -21.0% | 409,758 | -1.1% | 0.01% | +11.1% |
Q4 2019 | $34,916,000 | -18.4% | 414,324 | -27.6% | 0.01% | -25.0% |
Q3 2019 | $42,798,000 | +119.9% | 572,334 | +86.0% | 0.01% | +100.0% |
Q2 2019 | $19,459,000 | +7.2% | 307,741 | -18.3% | 0.01% | +20.0% |
Q1 2019 | $18,147,000 | +274.0% | 376,728 | +160.0% | 0.01% | +150.0% |
Q4 2018 | $4,852,000 | -56.5% | 144,908 | -31.9% | 0.00% | -33.3% |
Q3 2018 | $11,155,000 | +2.5% | 212,890 | -38.8% | 0.00% | 0.0% |
Q2 2018 | $10,882,000 | +43.7% | 347,686 | +0.1% | 0.00% | +50.0% |
Q1 2018 | $7,573,000 | +255.4% | 347,392 | +229.4% | 0.00% | +100.0% |
Q4 2017 | $2,131,000 | -97.8% | 105,463 | -97.8% | 0.00% | -95.8% |
Q3 2017 | $97,015,000 | +12.4% | 4,887,452 | -2.0% | 0.02% | +9.1% |
Q2 2017 | $86,293,000 | +14258.2% | 4,988,007 | +6617.7% | 0.02% | – |
Q1 2017 | $601,000 | -17.7% | 74,252 | -20.1% | 0.00% | – |
Q4 2016 | $730,000 | +453.0% | 92,955 | +501.1% | 0.00% | – |
Q3 2016 | $132,000 | -42.4% | 15,464 | -21.1% | 0.00% | – |
Q2 2016 | $229,000 | -45.6% | 19,605 | -32.5% | 0.00% | – |
Q1 2016 | $421,000 | -73.6% | 29,033 | -59.3% | 0.00% | – |
Q4 2015 | $1,596,000 | – | 71,356 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |